Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Screening for Genetic Mutations Predict Preterm Birth Defects

By Biotechdaily staff writers
Posted on 12 Feb 2008
Genetic mutations in the enzyme methylenetetrahydrofolate reductase (MTHFR) and coagulation protein factor V appear to have significant association with blood clots and tissue injury to the placenta and developing baby.

MTHFR is an enzyme related to amino acid metabolism. More...
Intrauterine growth restriction results in malnutrition of the developing fetus and babies of low birth weight, and can be related to a host of factors usually reflective of the mother's health, including infection, high blood pressure, and use of tobacco, alcohol, or illicit drugs. Factor V is a protein of the coagulation system, sometimes referred to as proaccelerin or labile factor.

Defined as any birth prior to 37 weeks gestation, preterm birth affects some 12% of pregnancies in the United States. A recent study from the U.S. Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA) found that preterm birth contributed to more than a third of infant deaths--twice as many as previously thought and making it the leading cause of infant deaths --yet the underlying causes of premature birth remain poorly understood. Babies who do survive face risks related to cerebral palsy, mental retardation, chronic lung disease, and vision and hearing loss, as well as other developmental problems.

Scientists from the University of Pittsburgh School of Medicine (Pittsburgh, PA, USA) analyzed DNA from placental tissue samples and cord blood from 111 women and their babies, finding that one fetal single nucleotide polymorphism (SNP) in MTHFR and one fetal SNP in factor V demonstrated "highly significant association with thrombotic and inflammatory lesions,” irrespective of adjustment for maternal race, smoking, and lower genital tract infection, all of which can contribute to genetic mutation. Women and babies with MTHFR mutation were 4.2 times more likely to exhibit blood clots and injury to placental tissue than those without the mutation. For those with factor V mutation, the association was less pronounced, but still elevated.

"This indicates a possible genetic predisposition to a condition of real clinical consequence in terms of intrauterine growth restriction, preeclampsia, and spontaneous preterm birth,” said Hyagriv Simhan, M.D., assistant professor of obstetrics, gynecology, and reproductive sciences at the University of Pittsburgh School of Medicine.

The study was presented at the 28th annual meeting of the Society for Maternal-Fetal Medicine, which was held in Dallas (TX, USA) from January 28 to February 2, 2008.


Related Links:
U.S. Centers for Disease Control and Prevention
University of Pittsburgh School of Medicine

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Portable Electronic Pipette
Mini 96
New
Urine Chemistry Control
Dropper Urine Chemistry Control
New
Automated MALDI-TOF MS System
EXS 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Ultrasensitive NeXT Personal Test detects the earliest molecular signs of recurrence in breast cancer patients (Photo courtesy of Personalis)

Ultrasensitive Test Could Identify Earliest Molecular Signs of Metastatic Relapse in Breast Cancer Patients

HR+ (hormone receptor-positive) HER2- (human epidermal growth factor receptor 2-negative) breast cancer represents over 70% of all breast cancer cases and carries a significant risk of late recurrence.... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.